<DOC>
	<DOCNO>NCT01146444</DOCNO>
	<brief_summary>Part I : investigate efficacy different sunscreen prevention skin lesion follow standardized photoprovocation Ultraviolet A/Ultraviolet B ( UVA/UVB ) light patient CLE . Part II : evaluate influence different sunscreen expression biomarkers skin patient CLE Healthy Controls follow UV irradiation .</brief_summary>
	<brief_title>Sunscreens Patients With Cutaneous Lupus Erythematosus ( CLE )</brief_title>
	<detailed_description>Part I Part I-interventions : - Experimental intervention : Application broad-spectrum sunscreen low , medium , high Sun Protection Factor ( SPF ) random order uninvolved skin area prior standardize photoprovocation . - Control intervention : Intra-individual application vehicle random order ; standardize photoprovocation vehicle treat untreated area . Part II Part II-interventions : - Experimental intervention : Application broad-spectrum sunscreen high SPF uninvolved skin area prior UV irradiation . - Control intervention : UV irradiation untreated area .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>Patients subacute cutaneous lupus erythematosus ( SCLE ) , discoid lupus erythematosus ( DLE ) , lupus erythematosus tumidus ( LET ) accord DÃ¼sseldorf Classification 2004 ( Kuhn Ruzicka 2004 ) confirm histological analysis . Women childbearing potential negative pregnancy test screening ( urine test ) use medically accept contraceptive regimen ( intrauterine device , partner 's vasectomy , &gt; 3 month previous hormonal contraception ( oestrogen plus gestagen pill , depot injection , subcutaneous depot ) combine barrier method ( preservative , vaginal diaphragm , cervical cap , spermicide ) study 8 week last UV exposure . Women clinically sterile ( postmenopausal , undergone hysterectomy tubal ligation ) . Actively cooperate participate study , follow instruction investigator attend centre agree time . Development skin lesion time current systemic treatment patient receive systemic medication treatment CLE . Signed informed consent form nature study fully explain . Pregnancy lactation woman positive pregnancy test . Known hypersensitivity allergic contact reaction component study agent . Treatment photosensitize drug . Exposure direct natural ( sunlight ) artificial UV radiation back within 4 week prior enter study . History another photodermatosis , except polymorph light eruption ( PLE ) . Any current know skin malignancy history skin malignancy within previous 5 year Xeroderma pigmentosum . Initiation change dose current systemic medication treatment CLE within 8 week prior standardize photoprovocation . Local therapy treatment CLE within two week prior standardize photoprovocation back patient Acute exacerbation CLE skin disease within 2 week prior enter study . Acute illness within 7 day prior phototesting major illness include infection hospitalization within 1 month study entry . AntidsDNA ( RIA ) &gt; 7 U/ml and/or least one follow criterion : Serositis : pleuritis pericarditis document electrocardiogram rub evidence pericardial effusion ; Renal disorder : proteinuria great 0.5 g/d great 3+ , cellular cast ; Neurologic disorder : seizure psychosis without cause . Patients document HIV and/or hepatitis B C infection . Any medical condition , would place subject undue risk , make unlikely followupmeasurements could obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Sunscreening Agents</keyword>
</DOC>